Join
Live feed
·
INSIDERFilingvia Quantisnow
Acumen Pharmaceuticals Inc. logo

Director Drapkin Kimberlee C was granted 35,500 shares, increasing direct ownership by 277% to 48,300 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ABOS· Acumen Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ABOS (Acumen Pharmaceuticals Inc.) and more on Quantisnow.